Evaluation of quality of life before and after repair of biliary surgical injury, resolved by specialists in a high-volume center

Abstract

DCP 2.8 ng/mL. Fifty percent of the cohort had a complete response to DEB-TACE. Univariate analysis revealed BALAD score was significantly associated with treatment response (p = 0.04). Seventy-two percent of patients with BALAD score 2 had incomplete treatment response. Analysis of individual BALAD components revealed no independent association with treatment or complete response. Bilirubin levels were significantly increased with decreasing BALAD albumin thresholds. The BALAD score was modified by altering the biomarker thresholds. Modified BALAD was significantly associated with treatment (p = 0.02) and complete response (p = 0.04). Twenty-two pecent of patients had disease progression defined as rising AFP (>400 ng/mL), multifocal disease, or metastatsis. Only 5% of patients with modified BALAD score 1 had disease progression. Conclusion: Modification of biomarker components from the BALAD score provides insight into treatment response in HCC patients awaiting transplantation.